IN2012DN00969A - - Google Patents

Info

Publication number: IN2012DN00969A
Authority: IN; India
Prior art keywords: antisense oligonucleotide; chemotherapeutic agent; tgf; beta; dacarbacine
Prior art date: 2009-07-30

Application number

Other languages

English (en)

Inventor

Karl-Hermann Schlingensiepen

Frank Jaschinski

Tanja Rothammer

Anneliese Schneider

Original Assignee

Antisense Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-30

Filing date

2010-07-30

Publication date

2015-04-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41278403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00969(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-07-30 Application filed by Antisense Pharma Gmbh filed Critical Antisense Pharma Gmbh

2015-04-10 Publication of IN2012DN00969A publication Critical patent/IN2012DN00969A/en

Links

108091034117 Oligonucleotide Proteins 0.000 abstract 4
239000000074 antisense oligonucleotide Substances 0.000 abstract 4
238000012230 antisense oligonucleotides Methods 0.000 abstract 4
239000002246 antineoplastic agent Substances 0.000 abstract 3
229940127089 cytotoxic agent Drugs 0.000 abstract 3
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
229960004316 cisplatin Drugs 0.000 abstract 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
230000003013 cytotoxicity Effects 0.000 abstract 1
231100000135 cytotoxicity Toxicity 0.000 abstract 1
-1 dacarbacine Chemical compound 0.000 abstract 1
229960003668 docetaxel Drugs 0.000 abstract 1
229960002949 fluorouracil Drugs 0.000 abstract 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
229960005277 gemcitabine Drugs 0.000 abstract 1
229960004768 irinotecan Drugs 0.000 abstract 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
229960001756 oxaliplatin Drugs 0.000 abstract 1
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000035945 sensitivity Effects 0.000 abstract 1
229960001603 tamoxifen Drugs 0.000 abstract 1
229960004964 temozolomide Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

IN969DEN2012 2009-07-30 2010-07-30 IN2012DN00969A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09166893		2009-07-30
PCT/EP2010/061152 WO2011012713A1 (fr)	2009-07-30	2010-07-30	Combinaison d'un agent chimiothérapique et d'un inhibiteur du système tgf- bêta

Publications (1)

Publication Number	Publication Date
IN2012DN00969A true IN2012DN00969A (fr)	2015-04-10

Family

ID=41278403

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN969DEN2012 IN2012DN00969A (fr)	2009-07-30	2010-07-30

Country Status (17)

Country	Link
US (1)	US8476246B2 (fr)
EP (1)	EP2340308B1 (fr)
JP (1)	JP2013500313A (fr)
KR (1)	KR20120107456A (fr)
CN (1)	CN102712924A (fr)
AU (1)	AU2010277554B2 (fr)
BR (1)	BR112012002102A2 (fr)
CA (1)	CA2769618A1 (fr)
CL (1)	CL2012000247A1 (fr)
CO (1)	CO6511199A2 (fr)
EC (1)	ECSP12011689A (fr)
IL (1)	IL217821A0 (fr)
IN (1)	IN2012DN00969A (fr)
MX (1)	MX2012001244A (fr)
PE (1)	PE20121495A1 (fr)
RU (1)	RU2012107535A (fr)
WO (1)	WO2011012713A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030158143A1 (en) *	2002-01-17	2003-08-21	Martin Gleave	Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
CN103517990A (zh)	2010-10-07	2014-01-15	通用医疗公司	癌症生物标志物
TWI454281B (zh) *	2011-10-06	2014-10-01	Nat Univ Tsing Hua	硼酸於硼中子捕獲治療肝癌之用途
WO2013124869A2 (fr) *	2012-02-21	2013-08-29	Amrita Vishwa Vidyapeetham University	Technique, méthode, manière, procédé et système associés à des plaquettes polymères fibreuses biodégradables pour l'administration locale d'agents thérapeutiques en combinaisons
US20140275214A1 (en) *	2013-03-14	2014-09-18	Teva Pharmaceutical Industries, Ltd.	Custirsen treatment with reduced toxicity
WO2015177329A1 (fr) *	2014-05-23	2015-11-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes permettant de déterminer la possibilité de réponse d'un patient à une radiothérapie
US10301624B2 (en)	2014-06-25	2019-05-28	The General Hospital Corporation	Targeting human satellite II (HSATII)
US11759530B2 (en) *	2014-11-17	2023-09-19	City Of Hope	TKI permeability enhancers
JP2018524588A (ja)	2015-06-26	2018-08-30	ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド	骨髄由来サプレッサー細胞中のテトラスパニン３３（Ｔｓｐａｎ３３）を標的化するがん療法
WO2017138925A1 (fr)	2016-02-09	2017-08-17	Autotelic Llc	Combinaisons antitumorales d'oligonucléotides antisens et d'agents anticancéreux
US9758786B2 (en) *	2016-02-09	2017-09-12	Autotelic, Llc	Compositions and methods for treating pancreatic cancer
KR20180103816A (ko)	2016-02-09	2018-09-19	오토텔릭 엘엘씨	췌장암을 치료하기 위한 조성물과 방법
US11459568B2 (en)	2016-10-31	2022-10-04	University Of Massachusetts	Targeting microRNA-101-3p in cancer therapy
US11471515B2 (en)	2016-11-09	2022-10-18	The Brigham And Women's Hospital, Inc.	Restoration of tumor suppression using MRNA-based delivery system
AU2019217875A1 (en)	2018-02-06	2020-08-20	Icahn School Of Medicine At Mount Sinai	Repeat RNA as biomarkers of tumor immune response
WO2020186124A1 (fr) *	2019-03-14	2020-09-17	The Research Foundation For The State University Of New York	Miarn modifiés et leur utilisation dans le traitement du cancer
GB201908012D0 (en) *	2019-06-05	2019-07-17	Io Biotech Aps	TGF-Beta vaccine
CN112933238A (zh) *	2021-02-02	2021-06-11	石河子大学	抑制TGF-βR1基因表达的物质与顺铂在治疗和/或预防食管癌中的应用
CN113425855B (zh) *	2021-06-28	2023-11-07	深圳瑞吉生物科技有限公司	一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3854480A (en)	1969-04-01	1974-12-17	Alza Corp	Drug-delivery system
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en)	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
JP2547714B2 (ja)	1981-10-23	1996-10-23	モルキユラ− バイオシステムズインコ−ポレテツド	オリゴヌクレオチド治療剤及びその製法
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
US4452775A (en)	1982-12-03	1984-06-05	Syntex (U.S.A.) Inc.	Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en)	1986-10-24	1991-12-24	Southern Research Institute	Method of potentiating an immune response
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5539082A (en)	1993-04-26	1996-07-23	Nielsen; Peter E.	Peptide nucleic acids
US5714331A (en)	1991-05-24	1998-02-03	Buchardt, Deceased; Ole	Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en)	1993-11-22	1998-02-17	Buchardt, Deceased; Ole	Peptide nucleic acids having amino acid side chains
US5407686A (en)	1991-11-27	1995-04-18	Sidmak Laboratories, Inc.	Sustained release composition for oral administration of active ingredient
US5736152A (en)	1995-10-27	1998-04-07	Atrix Laboratories, Inc.	Non-polymeric sustained release delivery system
EP0856579A1 (fr) *	1997-01-31	1998-08-05	BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH	Procédé pour la préparation d'oligonucléotides antisens
US7795232B1 (en)	2000-08-25	2010-09-14	Genta Incorporated	Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6809118B2 (en) *	2002-07-25	2004-10-26	Yih-Lin Chung	Methods for therapy of radiation cutaneous syndrome
DE112004001603T5 (de) *	2003-09-04	2006-07-06	Nihon University	TGF-β-Genexpressionsinhibitor
ZA200602941B (en) *	2003-11-13	2007-07-25	Genentech Inc	Screening assays and methods of tumor treatment
EP1682890A2 (fr) *	2003-11-13	2006-07-26	Genentech, Inc.	Dosages de criblage et procedes de traitement de tumeur
CA2550058C (fr) *	2003-12-19	2016-07-12	Antisense Pharma Gmbh	Composition pharmaceutique comprenant un oligonucleotide antisens anti-tgf-beta2 et un agent chimiotherapeutique
MXPA06009794A (es) *	2004-02-27	2007-03-15	Antisense Pharma Gmbh	Composicion farmaceutica.
US20090186076A1 (en) *	2006-02-01	2009-07-23	Kazunori Kataoka	Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent
JP5322476B2 (ja) *	2008-03-31	2013-10-23	テルモ株式会社	リポソームの製造装置およびリポソームの製造方法

2010
- 2010-07-30 MX MX2012001244A patent/MX2012001244A/es active IP Right Grant
- 2010-07-30 US US13/059,623 patent/US8476246B2/en active Active
- 2010-07-30 KR KR1020127005337A patent/KR20120107456A/ko not_active Withdrawn
- 2010-07-30 AU AU2010277554A patent/AU2010277554B2/en not_active Ceased
- 2010-07-30 EP EP10737580.0A patent/EP2340308B1/fr not_active Not-in-force
- 2010-07-30 PE PE2012000130A patent/PE20121495A1/es not_active Application Discontinuation
- 2010-07-30 BR BR112012002102A patent/BR112012002102A2/pt not_active IP Right Cessation
- 2010-07-30 CA CA2769618A patent/CA2769618A1/fr not_active Abandoned
- 2010-07-30 IN IN969DEN2012 patent/IN2012DN00969A/en unknown
- 2010-07-30 WO PCT/EP2010/061152 patent/WO2011012713A1/fr not_active Ceased
- 2010-07-30 CN CN2010800436805A patent/CN102712924A/zh active Pending
- 2010-07-30 RU RU2012107535/15A patent/RU2012107535A/ru not_active Application Discontinuation
- 2010-07-30 JP JP2012522185A patent/JP2013500313A/ja active Pending
2012
- 2012-01-29 IL IL217821A patent/IL217821A0/en unknown
- 2012-01-30 CL CL2012000247A patent/CL2012000247A1/es unknown
- 2012-02-23 EC ECSP12011689 patent/ECSP12011689A/es unknown
- 2012-02-29 CO CO12035227A patent/CO6511199A2/es unknown

Also Published As

Publication number	Publication date
MX2012001244A (es)	2012-03-26
EP2340308B1 (fr)	2014-12-24
US8476246B2 (en)	2013-07-02
EP2340308A1 (fr)	2011-07-06
JP2013500313A (ja)	2013-01-07
ECSP12011689A (es)	2012-06-29
PE20121495A1 (es)	2012-11-19
US20120027873A1 (en)	2012-02-02
CN102712924A (zh)	2012-10-03
CL2012000247A1 (es)	2013-07-05
RU2012107535A (ru)	2013-09-10
AU2010277554A1 (en)	2012-03-01
AU2010277554B2 (en)	2015-02-19
BR112012002102A2 (pt)	2017-05-02
CA2769618A1 (fr)	2011-02-03
KR20120107456A (ko)	2012-10-02
CO6511199A2 (es)	2012-08-31
WO2011012713A1 (fr)	2011-02-03
IL217821A0 (en)	2012-03-29

Publication	Publication Date	Title
IN2012DN00969A (fr)	2015-04-10
MX2010003299A (es)	2010-04-14	Oligonucleotidos muy cortos (micromirs).
IL219700B (en)	2018-02-28	Antiviral antisense oligonucleotides, preparations containing them and their uses
IL284154A (en)	2021-07-29	Analogues of oligonucleotides containing inter-subunit bonds and/or terminal groups, preparations containing them and their uses
MX2011013176A (es)	2012-04-30	Motivos de modificación química para inhibidores y miméticos del miarn.
IL255097A0 (en)	2017-12-31	Antimicrobial compounds, pharmaceutical preparations containing them and their uses
IL219912A (en)	2016-09-29	History of isoxazoline, their use as insecticides and their instrumentation
IL215799A (en)	2014-11-30	Quinazolone compounds, pharmaceuticals containing them and their uses
IL199615A (en)	2016-04-21	Urea factories glucokinase medications containing them and their use
IL219309A (en)	2015-03-31	History of glycoside, including pharmaceutical preparations and their use in the preparation of diabetes medications
IL214175A (en)	2015-09-24	Derivatives of aminotetralin, their pharmaceutical compositions and their use
ZA201007170B (en)	2012-01-25	Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
PL2051975T3 (pl)	2013-01-31	Podstawione prolinamidy, ich wytwarzanie oraz ich zastosowanie jako środków leczniczych
ZA201200367B (en)	2012-11-28	Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
IL223463A (en)	2016-12-29	Urea History, Pharmaceutical Preparations Containing and Uses
MX2015010083A (es)	2016-04-26	Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
MX2010009782A (es)	2010-09-30	Tratamientos antitumorales mejorados.
IL218277B (en)	2018-08-30	Tetracycline compounds, pharmaceutical preparations containing them and their use for the preparation of medicines for the treatment and prevention of infection
ZA200905668B (en)	2010-10-27	Fabric treatment compositions, their manufacture and use
GEP20115158B (en)	2011-02-10	Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction
MA34933B1 (fr)	2014-03-01	Preparation de nouveaux bio-composites chitosan-argile modifiee
WO2011050994A3 (fr)	2011-06-23	Closthioamides
WO2014001988A3 (fr)	2014-11-20	Utilisation de l'arnsi de ctbp1 pour le traitement du cancer de l'estomac
TNSN08442A1 (en)	2010-04-14	2-alkoxy-3,4,5-trihydroxy-alkylamide-benzothiazepines, the preparation and use thereof, and compositions containing the same
IN2013MU02985A (fr)	2015-10-09